{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:07:02Z","timestamp":1783537622465,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangdong Provincial Key Laboratories in Higher Education Institutions","award":["2019KSYS004"],"award-info":[{"award-number":["2019KSYS004"]}]},{"name":"Shenzhen Bay Laboratory Open Fund Project","award":["SZBL2021080601003"],"award-info":[{"award-number":["SZBL2021080601003"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32070718"],"award-info":[{"award-number":["32070718"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic colorectal cancer (CRC) harboring KRAS mutations presents a major therapeutic challenge due to its aggressive nature, poor prognosis, and resistance to EGFR-targeted therapies. This study aimed to identify novel drivers of metastasis specifically in KRAS-mutant CRC and to elucidate the underlying molecular mechanisms to undercover new therapeutic vulnerabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated data from clinical databases (TCGA, CPTAC) with experimental validation using human CRC cell lines, a tissue microarray, and two distinct\u00a0in vivo\u00a0metastasis models (liver and lung colonization). ZBTB20 expression and function were analyzed by IHC, Western blotting, Transwell assays, and RNA-seq integrated with ChIP-seq data. The mechanism of ZBTB20 regulation was investigated via co-immunoprecipitation, mass spectrometry, truncation analysis, site-directed mutagenesis, and luciferase reporter assays. Statistical significance was determined using Student\u2019s t-tests, ANOVA, and survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ZBTB20 expression was significantly upregulated with metastatic progression specifically in KRAS-mutant CRC patients and correlated with reduced overall survival. Functionally, ZBTB20 promoted CRC cell migration, invasion, EMT in vitro, and\u00a0drove\u00a0metastatic colonization in vivo. Mechanistically, KRAS\/ERK signaling directly phosphorylated ZBTB20 at Threonine 138, 142, and 232, a step essential for its nuclear localization and pro-metastatic activity. Integrating transcriptomic and cistromic data, we identified TGFBR2 as a direct transcriptional target of activated ZBTB20. Notably, pharmacological degradation of TGFBR2 with the inhibitor ITD-1 potently abrogated metastatic outgrowth in both liver and lung colonization models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings delineate a novel KRAS-ERK-ZBTB20-TGFBR2 signaling axis that is a critical driver of metastasis colonization in KRAS-mutant CRC. The robust efficacy of a TGFBR2 degrader in multiple\u00a0in vivo\u00a0models validates this axis as a viable therapeutic target, offering a promising strategy to inhibit metastatic progression in patients with this aggressive disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03619-w","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T05:36:25Z","timestamp":1767418585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KRAS-ERK signaling drives metastasis in colorectal cancer via phosphorylation-dependent activation of the ZBTB20-TGFBR2 axis"],"prefix":"10.1186","volume":"45","author":[{"given":"Qincheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vega-Rub\u00edn-de-Celis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runya","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"3619_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21798","volume":"74","author":"H Sung","year":"2024","unstructured":"Sung H, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:209\u201350. https:\/\/doi.org\/10.3322\/caac.21798.","journal-title":"CA Cancer J Clin"},{"key":"3619_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21900","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:7\u201333. https:\/\/doi.org\/10.3322\/caac.21900.","journal-title":"CA Cancer J Clin"},{"key":"3619_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.21037\/hbsn-23-145","volume":"14","author":"C Wu","year":"2025","unstructured":"Wu C, et al. Key prognostic factors in surgically treated colorectal liver metastases. Hepatobiliary Surg Nutr. 2025;14:501\u201316. https:\/\/doi.org\/10.21037\/hbsn-23-145.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"3619_CR4","doi-asserted-by":"publisher","first-page":"110754","DOI":"10.1016\/j.cellsig.2024.110754","volume":"115","author":"M Krausova","year":"2024","unstructured":"Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and colorectal cancer. Cell Signal. 2024;115:110754. https:\/\/doi.org\/10.1016\/j.cellsig.2024.110754.","journal-title":"Cell Signal"},{"key":"3619_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-i","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759\u201367. https:\/\/doi.org\/10.1016\/0092-8674(90)90186-i.","journal-title":"Cell"},{"key":"3619_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3149","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, et al. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761\u201374. https:\/\/doi.org\/10.1038\/nrc3149.","journal-title":"Nat Rev Cancer"},{"key":"3619_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11\u201322. https:\/\/doi.org\/10.1038\/nrc969.","journal-title":"Nat Rev Cancer"},{"key":"3619_CR8","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626\u201334. https:\/\/doi.org\/10.1200\/JCO.2007.14.7116.","journal-title":"J Clin Oncol"},{"key":"3619_CR9","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2011.39.2007","volume":"29","author":"E van Cutsem","year":"2011","unstructured":"van Cutsem E, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2011;29:2011\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.39.2007.","journal-title":"J Clin Oncol"},{"key":"3619_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/ADN.2025.12.45","volume":"12","author":"N Sharma","year":"2025","unstructured":"Sharma N, et al. Beyond monotherapy: evolving combination therapies for KRAS G12C-mutant colorectal cancer. ASCO Daily News. 2025;12:45. https:\/\/doi.org\/10.1200\/ADN.2025.12.45.","journal-title":"ASCO Daily News"},{"key":"3619_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1470-2045(25)00352-3","volume":"26","author":"H Kim","year":"2025","unstructured":"Kim H, et al. Health-related quality of life in patients with KRAS G12C-mutated metastatic colorectal cancer: a multicenter analysis. Lancet Oncol. 2025;26:123\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(25)00352-3.","journal-title":"Lancet Oncol"},{"key":"3619_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00661-1","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih MG, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation. Lancet Oncol. 2022;23:115\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(21)00661-1.","journal-title":"Lancet Oncol"},{"key":"3619_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1917239.","journal-title":"N Engl J Med"},{"key":"3619_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.seminoncol.2023.05.004","volume":"52","author":"R Miller","year":"2025","unstructured":"Miller R, et al. KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: trial evidence and future prospects. Semin Oncol. 2025;52:133\u201343. https:\/\/doi.org\/10.1016\/j.seminoncol.2023.05.004.","journal-title":"Semin Oncol"},{"key":"3619_CR15","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.canmed.2024.3619","volume":"14","author":"D Akhoundova","year":"2025","unstructured":"Akhoundova D, et al. MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression by targeting RAS-pathway. Cancer Med. 2025;14:3223\u201331. https:\/\/doi.org\/10.1016\/j.canmed.2024.3619.","journal-title":"Cancer Med"},{"key":"3619_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa2020403","volume":"390","author":"DJ Sargent","year":"2024","unstructured":"Sargent DJ, et al. KRAS mutations and adjuvant therapy in patients with resected stage II or III colon cancer. N Engl J Med. 2024;390:221\u201333. https:\/\/doi.org\/10.1056\/NEJMoa2020403.","journal-title":"N Engl J Med"},{"key":"3619_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/cncr.31813","volume":"125","author":"W Cai","year":"2019","unstructured":"Cai W, et al. Prognostic value of KRAS mutation status after resection of colorectal cancer liver metastases. Cancer. 2019;125:448\u201357. https:\/\/doi.org\/10.1002\/cncr.31813.","journal-title":"Cancer"},{"key":"3619_CR18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350\u20136. https:\/\/doi.org\/10.1038\/nm.3967.","journal-title":"Nat Med"},{"key":"3619_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3454","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9 J. TGF signalling in context. Nat Rev Mol Cell Biol. 2012;13:616\u201330. https:\/\/doi.org\/10.1038\/nrm3454.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3619_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.stem.2012.04.025","volume":"11","author":"E Willems","year":"2012","unstructured":"Willems E, Cabral-Teixeira J, Schade D, Cai W, Reeves P, Bushway PJ, et al. Small molecule-mediated TGF-\u03b2 type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell. 2012;11:242\u201352. https:\/\/doi.org\/10.1016\/j.stem.2012.04.025.","journal-title":"Cell Stem Cell"},{"key":"3619_CR21","doi-asserted-by":"publisher","first-page":"eadg6229","DOI":"10.1126\/scitranslmed.adg6229","volume":"16","author":"G Zhao","year":"2024","unstructured":"Zhao G, Xue L, Weiner AI, Gong N, Adams-Tzivelekidis S, Wong J, et al. TGF-\u03b2R2 signaling coordinates pulmonary vascular repair after viral injury in mice and human tissue. Sci Transl Med. 2024;16:eadg6229. https:\/\/doi.org\/10.1126\/scitranslmed.adg6229.","journal-title":"Sci Transl Med"},{"key":"3619_CR22","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1158\/1078-0432.CCR-25-0388","volume":"30","author":"Prkci","year":"2025","unstructured":"Prkci. Prkci promotes colorectal cancer metastasis by phosphorylating and stabilizing \u03b2-catenin. Clin Cancer Res. 2025;30:3676\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0388.","journal-title":"Clin Cancer Res"},{"key":"3619_CR23","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3892\/or.2024.8686","volume":"41","author":"K Yu","year":"2024","unstructured":"Yu K, et al. Zinc finger and BTB domain-containing 20: a newly emerging regulator in cancer and immunity. Oncol Rep. 2024;41:2289\u201399. https:\/\/doi.org\/10.3892\/or.2024.8686.","journal-title":"Oncol Rep"},{"key":"3619_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.canlet.2013.04.012","volume":"336","author":"Y Li","year":"2013","unstructured":"Li Y, et al. ZBTB20 is a sequence-specific transcriptional repressor of c-Myc in hepatocellular carcinoma cells. Cancer Lett. 2013;336:209\u201317. https:\/\/doi.org\/10.1016\/j.canlet.2013.04.012.","journal-title":"Cancer Lett"},{"key":"3619_CR25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.biocel.2013.02.009","volume":"45","author":"J Liu","year":"2013","unstructured":"Liu J, et al. ZBTB20, a novel transcriptional repressor represses cell proliferation and acts as an independent prognostic marker in hepatocellular carcinoma. Int J Biochem Cell Biol. 2013;45:1027\u201334. https:\/\/doi.org\/10.1016\/j.biocel.2013.02.009.","journal-title":"Int J Biochem Cell Biol"},{"key":"3619_CR26","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.18632\/ijcep.1838","volume":"8","author":"X Zhang","year":"2015","unstructured":"Zhang X, et al. Downregulation of ZBTB20 promotes cell proliferation and migration in colorectal cancer. Int J Clin Exp Pathol. 2015;8:10983\u201390. https:\/\/doi.org\/10.18632\/ijcep.1838.","journal-title":"Int J Clin Exp Pathol"},{"key":"3619_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1097-2765(03)00338-6","volume":"14","author":"KF Ahmad","year":"1998","unstructured":"Ahmad KF, et al. Mechanism of SMRT corepressor recruitment by the BCL-6 BTB domain. Mol Cell. 1998;14:563\u201374. https:\/\/doi.org\/10.1016\/S1097-2765(03)00338-6.","journal-title":"Mol Cell"},{"key":"3619_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0326-6","author":"F Mattioli","year":"2015","unstructured":"Mattioli F, et al. De novo ZBTB20 mutations cause Primrose syndrome. Orphanet J Rare Dis. 2015. https:\/\/doi.org\/10.1186\/s13023-015-0326-6.","journal-title":"Orphanet J Rare Dis"},{"key":"3619_CR29","doi-asserted-by":"publisher","first-page":"e2456","DOI":"10.3892\/ijmm.2024.2456","volume":"53","author":"Y Feng","year":"2024","unstructured":"Feng Y, et al. Recent advances and molecular mechanisms of TGF-\u03b2 signaling in metastatic cancer. Int J Mol Med. 2024;53:e2456. https:\/\/doi.org\/10.3892\/ijmm.2024.2456.","journal-title":"Int J Mol Med"},{"key":"3619_CR30","doi-asserted-by":"publisher","first-page":"121345","DOI":"10.1016\/j.canlet.2023.121345","volume":"564","author":"S Wang","year":"2025","unstructured":"Wang S, et al. TGF-\u03b2 signaling in cancer: mechanisms of progression and therapy resistance. Cancer Lett. 2025;564:121345. https:\/\/doi.org\/10.1016\/j.canlet.2023.121345.","journal-title":"Cancer Lett"},{"key":"3619_CR31","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/s41598-024-68938-y","volume":"14","author":"SM Johnson","year":"2024","unstructured":"Johnson SM, et al. Investigating the WNT and TGF-beta pathways alterations and tumor heterogeneity in colorectal cancer. Sci Rep. 2024;14:2368. https:\/\/doi.org\/10.1038\/s41598-024-68938-y.","journal-title":"Sci Rep"},{"key":"3619_CR32","doi-asserted-by":"publisher","first-page":"1020222","DOI":"10.3389\/fcell.2022.1020222","volume":"10","author":"X Li","year":"2022","unstructured":"Li X, Wu Y, Tian T. TGF-\u03b2 signaling in Metastatic Colorectal Cancer (mCRC). Front Cell Dev Biol. 2022;10:1020222. https:\/\/doi.org\/10.3389\/fcell.2022.1020222.","journal-title":"Front Cell Dev Biol"},{"key":"3619_CR33","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41591-025-03642-3","volume":"31","author":"JP Smith","year":"2025","unstructured":"Smith JP, et al. Vaccine targeting KRAS in pancreatic and colorectal cancer shows promise in phase 1 trial. Nat Med News. 2025;31:900\u20131. https:\/\/doi.org\/10.1038\/s41591-025-03642-3.","journal-title":"Nat Med News"},{"key":"3619_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak S, ten Dijke P. Targeting TGF-\u03b2 signaling in cancer. Trends Cancer. 2017;3:56\u201371. https:\/\/doi.org\/10.1016\/j.trecan.2016.11.008.","journal-title":"Trends Cancer"},{"key":"3619_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00441-011-1241-3","volume":"347","author":"T Doetschman","year":"2012","unstructured":"Doetschman T, Barnett JV, Runyan RB, Camenisch TD, Heimark RL, Granzier HL, et al. Transforming growth factor beta signaling in adult cardiovascular diseases and repair. Cell Tissue Res. 2012;347:203\u201323. https:\/\/doi.org\/10.1007\/s00441-011-1241-3.","journal-title":"Cell Tissue Res"},{"key":"3619_CR36","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25587","volume":"554","author":"D Tauriello","year":"2018","unstructured":"Tauriello D, et al. TGF\u03b2 drives immune evasion in mouse models of colorectal cancer. Nature. 2018;554:538\u201343. https:\/\/doi.org\/10.1038\/nature25587.","journal-title":"Nature"},{"key":"3619_CR37","doi-asserted-by":"publisher","first-page":"11005","DOI":"10.1111\/jcmm.17655","volume":"29","author":"X Zuo","year":"2025","unstructured":"Zuo X, et al. Research progress on the role of zinc finger protein in colorectal cancer. J Cell Mol Med. 2025;29:11005\u201318. https:\/\/doi.org\/10.1111\/jcmm.17655.","journal-title":"J Cell Mol Med"},{"key":"3619_CR38","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.1038\/s41388-019-0905-4","volume":"38","author":"S Beyes","year":"2019","unstructured":"Beyes S, Andrieux G, Schrempp M, Aicher D, Wenzel J, Ant\u00f3n-Garc\u00eda P, et al. Genome-wide mapping of DNA-binding sites identifies stemness-related genes as directly repressed targets of SNAIL1 in colorectal cancer cells. Oncogene. 2019;38:6647\u201361. https:\/\/doi.org\/10.1038\/s41388-019-0905-4.","journal-title":"Oncogene"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03619-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03619-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03619-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:57:32Z","timestamp":1770040652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03619-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3619"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03619-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in accordance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC) of the\u00a0Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences (Approval No. SINH-2024-LLY-2). Male BALB\/c nude mice (6\u20138\u00a0weeks old) were used for all in vivo experiments. Metastatic burden was monitored by bioluminescence imaging (BLI) using an IVIS Spectrum system (PerkinElmer). Immunohistochemical staining was performed on a commercial human colorectal cancer tissue microarray (TMA) purchased from Shanghai Zhuoli Biotechnology Company Ltd. (Shanghai, China) under approval number SHLLS-BA-22101102. The vendor confirmed that all tissue samples were ethically sourced and collected under Institutional Review Board (IRB)-approved protocols with written informed consent obtained from all donors, in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}